NuCana (NASDAQ:NCNA) Price Target Cut to $25.00 by Analysts at Oppenheimer

NuCana (NASDAQ:NCNA) had its price objective cut by investment analysts at Oppenheimer from $150.00 to $25.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock.

Separately, William Blair lowered NuCana from an “outperform” rating to a “market perform” rating in a research note on Friday.

NuCana Stock Down 5.7 %

Shares of NCNA traded down $0.21 during midday trading on Tuesday, reaching $3.45. 25,979 shares of the stock were exchanged, compared to its average volume of 76,155. NuCana has a twelve month low of $2.53 and a twelve month high of $20.25. The company has a market cap of $9.11 million, a P/E ratio of -0.29 and a beta of 0.99. The stock’s 50 day simple moving average is $4.07 and its 200 day simple moving average is $4.94.

Institutional Trading of NuCana

A hedge fund recently bought a new stake in NuCana stock. Baillie Gifford & Co. bought a new position in shares of NuCana plc (NASDAQ:NCNA) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 146,360 shares of the company’s stock, valued at approximately $378,000. Baillie Gifford & Co. owned 5.54% of NuCana at the end of the most recent reporting period. Hedge funds and other institutional investors own 44.00% of the company’s stock.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.